Creacion Ventures is a venture capital firm with offices in Boston and Shanghai, focus on Newco formation and early stage investment within healthcare industry, particularly biopharma space.

Head of CoStone Capital(基石资本) healthcare investment team. CoStone Capital is a China PE fund with 15 year history, headquartered in Shenzhen with office in Shanghai, Beijing, Hefei and AUM c.40 billion RMB. CoStone Capital has invested more than 100 companies in the past 15 years with 35 exits incl. more than 20 IPOs(not incl. NEEQ) .

Responsible for deal sourcing, due diligence, transaction and portfolio management.LAV is the Asian venture arm of Eli Lilly &Co., a top10 MNC pharmaceutical company. LAV makes venture capital/growth capital investments in the life sciences and healthcare sectors in Asia, particularly China.LAV invests exclusively in the life sciences and healthcare industries, includes:· Pharmaceuticals · Medical devices and diagnostics · Healthcare services – hospitals, clinics, etc.· Animal health

A global Top 10 strategic consulting firm with strong life-science practice in China Highlighted Case Experience- In-license assessment of a phase II cholesterol-lowering pipeline product for a global leading pharmaceutical company: China hypercholesteremia market study including market size, growth and competitive landscape; Target product and competition products clinical development timeline analysis; Target product revenue forecast under different price and reimbursement scenario, risk-adjusted P&L forecast and NPV analysis- Market assessment of an innovative clinical phase II oral anti-anemic drug indicated for non-dialysis Chronic Kidney Disease Stage 5(CKD5) anemia patients for a start-up company: China non-dialysis CKD5 anemia market sizing and forecasting; Product treated patient population forecasting under different scenarios- China aortic intervention stent graft market study and 5-year growth strategy development for a global leading medical device company, including market size, growth and competition assessment, channel dynamic analysis, customer demand and behavior identification concluded with strategic recommendation- Develop China brand generic strategy for a global leading MNC pharma: China off-patent originator(OPO) and generic drug(Gx) market dynamic study incl. provincial tendering, hospital listing, distribution and marketing and sales dynamic read-out; Brand generic product portfolio prioritization based on agreed value proposition and focus hospital segment; Brand generic business structure and operational plan design, incl. team structure design, provincial tendering operational plan, target hospital segment listing strategy, team resource planning and KPI design- China medical devices distribution market opportunity prioritization to identify high value-added and actionable business for a global leading healthcare distribution company to help its China market entry

China Top 3 3A general hospital, Top 3 ranking Cardiovascular Center- Comprehensive knowledge and first-hand clinical experience in intervention cardiology with deep understanding of current treatment paradigm, clinical unmet needs and future developing trends. Master clinical expertise of coronary intervention and familiar with arrhythmia ablation and pacemaker implantation- Master the application of various medical device/equipment including percutaneous cardiac intervention(PCI) related device (stent, guidewire, catheter, etc.), pacemaker, ventilator and cardiogram monitor, etc.- Master the diagnosis and treatment of common diseases